In an effort to further risk stratify prostate cancer patients and find markers for aggressive disease, genomic biomarkers have been integrated into clinical practice and include Prolaris (Myriad Genetics), Oncotype DX Prostate Cancer Assay (Genomics Health, Inc), transmembrane protease, serine 2 (TMPRSS-2), and prostate cancer antigen 3 (PCA3)7. This evidence concerns the gene TMPRSS2 and prostate carcinoma.